Subtype
Retroperitoneal Carcinoma
CI-CAN-00001463Explore in graph →
26 active trials1 approved drugs2 evidence items
- NCIt
- C7352
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001463Explore in graph →
Clinical trials
89 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (12)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03612232 | Cabozantinib in Advanced Adrenocortical Carcinoma(CaboACC) | unknown | Phase 2 | 37 | Wuerzburg University HospitalOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT04318730 | Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma | unknown | Phase 2 | 21 | West China HospitalOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06229405 | Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data | unknown | — | 8,200 | Seoul National University HospitalOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06050057 | Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy | unknown | — | 100 | University Hospital OlomoucOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05839886 | The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma(MEET) | unknown | — | 50 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | May 6, 2023 | clinicaltrials |
| NCT05763524 | European Multicenter Study on Role of Lymph Node Dissection in Surgical Management of Adrenal Cortical Carcinoma(LACC) | unknown | — | 90 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05660889 | Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma(AVS for ACC) | unknown | — | 25 | Erasmus Medical CenterOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03517332 | Circulating Tumor DNA Exposure in Peripheral Blood | unknown | — | 10,000 | Quantgene Inc.INDUSTRY | 2 | Nov 20, 2018 | clinicaltrials |
| NCT03257891 | Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines(CabACC) | unknown | Phase 2 | 25 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT03145285 | Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma(ABACUS) | unknown | Phase 2 | 10 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT00777244 | Efficacy of Adjuvant Mitotane Treatment (ADIUVO)(ADIUVO) | unknown | Phase 3 | 200 | University of Turin, ItalyOTHER | 7 | May 8, 2017 | clinicaltrials |
| NCT00786110 | Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients(PAXO) | unknown | Phase 2 | 30 | University of Turin, ItalyOTHER | 1 | Feb 24, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Aug 19, 2024source: clinicaltrials